Back

N-myristoyltransferase inhibition is synthetic lethal in MYC-deregulated cancers

Lueg, G. A.; Faronato, M.; Gorelik, A.; Goya Grocin, A.; Caamano-Gutierrez, E.; Falciani, F.; Solari, R.; Carr, R.; Bell, A. S.; Bartlett, E.; Hutton, J. A.; Llorian-Sopena, M.; Chakravarty, P.; Brzezicha, B.; Janz, M.; Garnett, M. J.; Calado, D. P.; Tate, E. W.

2021-03-20 cancer biology
10.1101/2021.03.20.436222 bioRxiv
Show abstract

Human N-myristoyltransferases (NMTs) catalyze N-terminal protein myristoylation, a modification regulating membrane trafficking and interactions of >100 proteins. NMT is a promising target in cancer, but a mechanistic rationale for targeted therapy remains poorly defined. Here, large-scale cancer cell line screens against a panel of NMT inhibitors (NMTi) were combined with systems-level analyses to reveal that NMTi is synthetic lethal with deregulated MYC. Synthetic lethality is mediated by post-transcriptional failure in mitochondrial respiratory complex I protein synthesis concurrent with loss of myristoylation and degradation of complex I assembly factor NDUFAF4, followed by mitochondrial dysfunction specifically in MYC-deregulated cancer cells. NMTi eliminated MYC-deregulated tumors in vivo without overt toxicity, providing a new paradigm in which targeting a constitutive co-translational protein modification is synthetically lethal in MYC-deregulated cancers. One-sentence summaryN-myristoyltransferase inhibition leads to post-transcriptional complex I failure and cell death in MYC-deregulated cancers

Matching journals

The top 3 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.